1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Multiple Sclerosis Drugs Market
2.3. Global Multiple Sclerosis Drugs Market, By Molecule, 2025 (US$ Million)
2.4. Global Multiple Sclerosis Drugs Market, By Route of Administration, 2025 (US$ Million)
2.5. Global Multiple Sclerosis Drugs Market, By Geography, 2025 (US$ Million)
2.6. Attractive Investment Proposition by Geography, 2025
3. Multiple Sclerosis Drugs Market: Competitive Analysis
3.1. Market Positioning of Key Multiple Sclerosis Drugs Market Vendors
3.2. Strategies Adopted by Multiple Sclerosis Drugs Market Vendors
4. Multiple Sclerosis Drugs Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Multiple Sclerosis Drugs Market Value, 2024 - 2034, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. Porter's Five Force Model
4.5.1. Supplier Power
4.5.2. Buyer Power
4.5.3. Threat Of Substitutes
4.5.4. Threat Of New Entrants
4.5.5. Competitive Rivalry
4.6. PESTEL Analysis
4.6.1. Political Landscape
4.6.2. Economic Landscape
4.6.3. Social Landscape
4.6.4. Technology Landscape
4.6.5. Environmental Landscape
4.6.6. Legal Landscape
5. Multiple Sclerosis Drugs Market: By Molecule, 2024-2034, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2025 Versus 2034
5.3. Market Segmentation
5.3.1. Biologics
5.3.2. Small Molecules
6. Multiple Sclerosis Drugs Market: By Route of Administration, 2024-2034, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2025 Versus 2034
6.3. Market Segmentation
6.3.1. Oral Therapeutic Drugs
6.3.2. Parenteral Therapeutic Drugs
7. North America Multiple Sclerosis Drugs Market, 2024-2034, USD (Million)
7.1. Market Overview
7.2. Multiple Sclerosis Drugs Market: By Molecule, 2024-2034, USD (Million)
7.3. Multiple Sclerosis Drugs Market: By Route of Administration, 2024-2034, USD (Million)
7.4. Multiple Sclerosis Drugs Market: By Region, 2024-2034, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Multiple Sclerosis Drugs Market: By Molecule, 2024-2034, USD (Million)
7.4.1.1.2. Multiple Sclerosis Drugs Market: By Route of Administration, 2024-2034, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Multiple Sclerosis Drugs Market: By Molecule, 2024-2034, USD (Million)
7.4.1.2.2. Multiple Sclerosis Drugs Market: By Route of Administration, 2024-2034, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Multiple Sclerosis Drugs Market: By Molecule, 2024-2034, USD (Million)
7.4.1.3.2. Multiple Sclerosis Drugs Market: By Route of Administration, 2024-2034, USD (Million)
8. UK and European Union Multiple Sclerosis Drugs Market, 2024-2034, USD (Million)
8.1. Market Overview
8.2. Multiple Sclerosis Drugs Market: By Molecule, 2024-2034, USD (Million)
8.3. Multiple Sclerosis Drugs Market: By Route of Administration, 2024-2034, USD (Million)
8.4. Multiple Sclerosis Drugs Market: By Region, 2024-2034, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Multiple Sclerosis Drugs Market: By Molecule, 2024-2034, USD (Million)
8.4.1.1.2. Multiple Sclerosis Drugs Market: By Route of Administration, 2024-2034, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Multiple Sclerosis Drugs Market: By Molecule, 2024-2034, USD (Million)
8.4.1.2.2. Multiple Sclerosis Drugs Market: By Route of Administration, 2024-2034, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Multiple Sclerosis Drugs Market: By Molecule, 2024-2034, USD (Million)
8.4.1.3.2. Multiple Sclerosis Drugs Market: By Route of Administration, 2024-2034, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Multiple Sclerosis Drugs Market: By Molecule, 2024-2034, USD (Million)
8.4.1.4.2. Multiple Sclerosis Drugs Market: By Route of Administration, 2024-2034, USD (Million)
8.4.1.5. France
8.4.1.5.1. Multiple Sclerosis Drugs Market: By Molecule, 2024-2034, USD (Million)
8.4.1.5.2. Multiple Sclerosis Drugs Market: By Route of Administration, 2024-2034, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Multiple Sclerosis Drugs Market: By Molecule, 2024-2034, USD (Million)
8.4.1.6.2. Multiple Sclerosis Drugs Market: By Route of Administration, 2024-2034, USD (Million)
9. Asia Pacific Multiple Sclerosis Drugs Market, 2024-2034, USD (Million)
9.1. Market Overview
9.2. Multiple Sclerosis Drugs Market: By Molecule, 2024-2034, USD (Million)
9.3. Multiple Sclerosis Drugs Market: By Route of Administration, 2024-2034, USD (Million)
9.4. Multiple Sclerosis Drugs Market: By Region, 2024-2034, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Multiple Sclerosis Drugs Market: By Molecule, 2024-2034, USD (Million)
9.4.1.1.2. Multiple Sclerosis Drugs Market: By Route of Administration, 2024-2034, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Multiple Sclerosis Drugs Market: By Molecule, 2024-2034, USD (Million)
9.4.1.2.2. Multiple Sclerosis Drugs Market: By Route of Administration, 2024-2034, USD (Million)
9.4.1.3. India
9.4.1.3.1. Multiple Sclerosis Drugs Market: By Molecule, 2024-2034, USD (Million)
9.4.1.3.2. Multiple Sclerosis Drugs Market: By Route of Administration, 2024-2034, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Multiple Sclerosis Drugs Market: By Molecule, 2024-2034, USD (Million)
9.4.1.4.2. Multiple Sclerosis Drugs Market: By Route of Administration, 2024-2034, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Multiple Sclerosis Drugs Market: By Molecule, 2024-2034, USD (Million)
9.4.1.5.2. Multiple Sclerosis Drugs Market: By Route of Administration, 2024-2034, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Multiple Sclerosis Drugs Market: By Molecule, 2024-2034, USD (Million)
9.4.1.6.2. Multiple Sclerosis Drugs Market: By Route of Administration, 2024-2034, USD (Million)
10. Latin America Multiple Sclerosis Drugs Market, 2024-2034, USD (Million)
10.1. Market Overview
10.2. Multiple Sclerosis Drugs Market: By Molecule, 2024-2034, USD (Million)
10.3. Multiple Sclerosis Drugs Market: By Route of Administration, 2024-2034, USD (Million)
10.4. Multiple Sclerosis Drugs Market: By Region, 2024-2034, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Multiple Sclerosis Drugs Market: By Molecule, 2024-2034, USD (Million)
10.4.1.1.2. Multiple Sclerosis Drugs Market: By Route of Administration, 2024-2034, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Multiple Sclerosis Drugs Market: By Molecule, 2024-2034, USD (Million)
10.4.1.2.2. Multiple Sclerosis Drugs Market: By Route of Administration, 2024-2034, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Multiple Sclerosis Drugs Market: By Molecule, 2024-2034, USD (Million)
10.4.1.3.2. Multiple Sclerosis Drugs Market: By Route of Administration, 2024-2034, USD (Million)
11. Middle East and Africa Multiple Sclerosis Drugs Market, 2024-2034, USD (Million)
11.1. Market Overview
11.2. Multiple Sclerosis Drugs Market: By Molecule, 2024-2034, USD (Million)
11.3. Multiple Sclerosis Drugs Market: By Route of Administration, 2024-2034, USD (Million)
11.4. Multiple Sclerosis Drugs Market: By Region, 2024-2034, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Multiple Sclerosis Drugs Market: By Molecule, 2024-2034, USD (Million)
11.4.1.1.2. Multiple Sclerosis Drugs Market: By Route of Administration, 2024-2034, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Multiple Sclerosis Drugs Market: By Molecule, 2024-2034, USD (Million)
11.4.1.2.2. Multiple Sclerosis Drugs Market: By Route of Administration, 2024-2034, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Multiple Sclerosis Drugs Market: By Molecule, 2024-2034, USD (Million)
11.4.1.3.2. Multiple Sclerosis Drugs Market: By Route of Administration, 2024-2034, USD (Million)
12. Company Profile
12.1. Abbvie, Inc. (Company Overview, Financial Performance, Product Portfolio, Strategic Initiatives)
12.2. Acorda Therapeutics
12.3. Acorda Therapeutics, Inc.
12.4. Bayer HealthCare
12.5. Biogen
12.6. Genzyme (Sanofi)
12.7. GlaxoSmithKline plc.
12.8. Merck Serono
12.9. Novartis International AG
12.10. Pfizer Inc.
12.11. Teva Pharmaceutical
